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Background. In newly diagnosed osteosarcoma (OS) patients, the time between surgery and resumption of chemotherapy is
2–7 weeks. Delays > 16 days are associated with increased risk of relapse and decreased overall survival. Identifying an
effective therapy that can be used postoperatively may prevent relapse. We investigated whether aerosol gemcitabine (GCB)
initiated after tumor resection inhibited the growth of OS lung metastases without affecting the wound-healing process.
Methods. Mice were injected intratibially with OS cells. Amputation was performed when the tumor reached 1.5 cm. Fullthickness excisional wounds were also made on the dorsal skin and tail. Aerosol GCB or PBS was initiated 48 hours after
amputation (3 times/week for 3 weeks). Wound sections were evaluated by immunohistochemistry for Ki-67 (proliferation),
CD31 (vessels), VEGF, IL-10, bFGF, mast cells, macrophages, and M1/M2 macrophage ratios. The lungs were analyzed for
macro- and micrometastases. Results. Aerosol GCB inhibited the growth of the lung metastases but had no effect on the 3
phases of wound healing in the dorsal skin, tail, or bone. Production of cytokines at the wound sites was the same. Conclusion.
These data indicate that initiating aerosol GCB postoperatively may kill residual lung metastases thereby preventing relapse
and improve survival.

1. Introduction
Osteosarcoma is the most common malignant bone tumor
in both adults and children. While the introduction of
combination chemotherapy given in addition to surgery
improved the overall survival from 20 to 65%, survival rates
have remained stagnant for >25 years [1–3]. The lung is most

common site of metastatic spread, and the majority of newly
diagnosed patients have undetectable microscopic lung
metastases at the time of diagnosis providing the rational for
giving preoperative and postoperative chemotherapy. Despite the use of aggressive combination chemotherapy, the
development of visible lung metastases continues to be the
major challenge in curing this disease. For patients who
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develop relapsed disease in the lung, the 5-year survival rate
is only 20% [4, 5], and second-line chemotherapy has not
made a significant impact on improving this outcome [6]. It
is therefore critical to eradicate these micrometastases
during the initial treatment period.
Prior to surgery, systemic chemotherapy serves to
control the growth and size of the primary tumor to decrease
the morbidity of surgery in addition to targeting the microscopic disease in the lung. Chemotherapy is stopped a few
weeks before and for several weeks after surgery due to the
interference of systemic chemotherapy on wound healing.
Once patients recover from surgery, chemotherapy is resumed to prevent macroscopic metastases from developing.
This results in a break or delay in chemotherapy administration, leaving patients untreated for a significant period of
time when tumor rebound is possible. It is therefore important that this delay be as short as possible. The standard
time between the surgery and the resumption of chemotherapy treatment is 2–4 weeks, but delays as much as 6–8
weeks have been reported in patients with postoperative
complications such as infection or other comorbidities that
lead to delayed healing [7–9]. Delays > 16 days have been
associated with an increased risk of relapse and a significant
decrease in overall survival [7, 8]. With 21–40% of patients
experiencing delays [7, 8], identifying an effective “bridge
therapy” against osteosarcoma lung metastases which does
not interfere with postoperative healing and can be used in
the immediate postoperative period has the potential to
prevent relapse and increase both the event-free and overall
survival.
Wound healing is complex and includes 3 distinct phases
[10, 11]. First is the inflammatory phase which consists of the
recruitment of inflammatory cells, including neutrophils,
mast cells, and macrophages, both M1 and M2. M2 macrophages promote cell proliferation and tissue repair, while
M1 macrophages inhibit cell proliferation. The second phase
involves the migration and proliferation of fibroblasts and
endothelial cells [12, 13]. Tissue remodeling is the third
phase. Several specific cytokines and growth factors are
critical to the healing process including IL-10 and bFGF
[14–17]. A potential bridge therapy candidate should not
interfere with any of the three wound-healing phases.
Gemcitabine (GCB) is a deoxycytidine analogue that
causes DNA damage, initiating cell death [18]. GCB given
systemically together with Taxol has shown modest activity
against relapsed large lung metastases [19]. The activity of
aerosol delivery to target OS lung metastases has been investigated. Aerosol therapy has the advantage of delivering
agents directly to the lung, the organ where micrometastases
exist, resulting in increased drug concentration in the lung,
decreased drug levels in the circulation, and decreased
systemic toxicity [20]. Using 1/10th the systemic dose, the
effect of aerosol GCB against human and mouse OS lung
metastases in vivo was demonstrated [21, 22]. Maximum
therapeutic activity was seen against microscopic disease.
Peak serum levels following 1.0 mg/kg aerosol GCB were
200 ng/ml, significantly lower than the peak serum levels
(700 ng/kg) following 1.0 mg/kg GCB given systemically. No
liver, kidney, lung, or hematologic toxicity was observed in
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the mice following 5 weeks of aerosol GCB given 3 times/wk.
In addition, aerosol GCB demonstrated significant therapeutic benefit in dogs with visible osteosarcoma lung metastases [23]. Finally, Phase I/II trials using aerosol GCB
demonstrated that this therapeutic approach is safe with no
significant toxicity in regard to organ function or hematologic effects [24]. Taken together, these studies indicate
that aerosol GCB may be a candidate for bridge therapy
between the surgery and the restarting of systemic chemotherapy. However, there are no data in mice or patients
on whether aerosol GCB affects wound healing.
We therefore wished to determine whether aerosol delivery of GCB is effective against OS lung metastases without
interfering with wound healing in the skin and the bone
following limb amputation. We evaluated the in vivo effect of
aerosol GCB initiated 48 hours after amputation of a primary OS tumor in the tibia on established OS lung metastases and the healing of bone, dorsal skin, and tail
wounds. While aerosol GCB successfully eradicated the
microscopic lung metastases, aerosol GCB had no significant
effect on the in vivo wound-healing process.

2. Materials and Methods
2.1. Cell Lines. K7M3 murine osteosarcoma metastatic cells
[21] were cultured in Dulbecco’s modified Eagle’s medium
(DMEM) and supplemented with 10% fetal calf serum
(HyClone, USA) and 1% penicillin/streptomycin (Lonza,
USA). The cells were maintained at 37°C in a humidified
atmosphere of 5% carbon dioxide in air and harvested at
80–90% confluency.
2.2. Animal Model. BALB/c mice (Charles River, USA)
were anesthetized with isoflurane. K7M3 cells suspended
in 10 µl of sterile phosphate-buffered saline (PBS) at
a density of 1 ×106 cells were injected into the tibia as
previously described [22, 25]. Local tumors were detected
at 3-4 weeks after injection, and the metastases were
visible by 5-6 weeks [25].
2.3. Amputation. When tumor size reached 1.5 cm in diameter, the mouse was anesthetized with isoflurane and the
leg was amputated above the knee joint with a sterile blade
followed by the application of surgical staples. To minimize
the postoperative pain, buprenorphine (0.1 mg/kg) was
given as s.c. injection every 8–12 hours. The amputation
wound was monitored thereafter during the aerosol PBS and
GCB treatment.
2.4. Preparation of Wound Tissue. Mice were also used in the
dorsal cutaneous and tail wound experiments one day after
amputation. The mice were anesthetized with isoflurane, and
the dorsal cutaneous skin was shaved and wiped with 70%
ethanol. Full-thickness excisional wounds were made by
picking up a fold of skin using a sterile disposable 6 mm
biopsy punch, resulting in the generation of one wound
on each side of the midline [26, 27]. A separate tail wound
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2.5. Aerosol GCB Treatment. Ten mice were treated with
aerosol PBS (control) or aerosol GCB at 1.0 mg/kg in 10 ml
saline. For comparison of serum GCB concentration, 10 mice
were treated with intraperitoneal injection of 1.0 mg/kg GCB in
0.2 ml of normal saline 3 times weekly for 3 weeks as previously
described [22]. Blood was collected in tubes containing 0.75 mg
of tetrahydrouridine, a cytidine deaminase inhibitor, to
prevent ex vivo metabolism of gemcitabine. Blood samples were processed to separate plasma and kept at −80°C
until analysis. Serum was collected at 10 min, 30 min, and
24 hours after GCB treatment. Samples were sent to Pharmacy
Pharmacology Research Department for analysis of the serum
GCB level.
2.6. Histology and Immunohistochemistry. Tissues from the
amputation wound and dorsal cutaneous and tail wounds
were collected on days 7, 14, and two months after the
surgery and aerosol GCB treatment. Tissue sections were
formalin fixed and paraffin embedded. Decalcification was
performed for the amputation wound.
Mast cell numbers were quantified using toluidine blue
staining and counting the number of toluidine blue positive cells in 10 high-power field (h.p.f) under a 20x objective lens.
The total number of macrophages was quantified using
anti-F4/80 antibody staining (ab6640, Abcam USA). M1
macrophages were identified and quantified using iNOS
staining (PA5-16855, Thermo Fisher Scientific). Anti-mannose
receptor antibody (ab 64,693, Abcam USA) was used to identify
and quantify M2 macrophages. CD31 antibody (ab 28,364,
Abcam USA) was used for endothelial cell staining; antiVEGFR-2 (ab39256, Abcam USA) was used for VEGF staining;
IL-10 and FGF-2 were measured using ab189392 (Abcam USA)
and sc-1360 (Santa Cruz Biotechnology), respectively. Ki67
antibody (ab15580, Abcam USA) was used for cell proliferation
and fibroblast activation; protein alpha antibody (ab53066,
Abcam USA) was used for fibroblast staining. All the
sections were incubated with the primary antibody overnight at 4°C in accordance with the protocols provided by
companies.
2.7. Statistics. To determine the significance between two
groups, we used GraphPad Prism. The statistical analysis
between two groups was performed using the unpaired
Student’s t-test. P > 0.05 was considered to have no significant difference.

700.0
Gemcitabine serum level (ng/ml)

10 mm × 3 mm was made on the tail of each mouse down to
the fascia on the same day as the dorsal wound. The two
wounds were photographed every 3 days, and dimensions
were measured every 3 days, particularly noting reepithelialization of the skin [28].
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Figure 1: Serum GCB levels following intraperitoneal (i.p.) and
aerosol GCB. Mice were treated with 1 mg/kg GCB given i.p. or by
aerosol administration. Blood was collected at various times following administration, and serum GCB levels were quantified.
Mice treated with aerosol GCB had significantly lower serum levels
(P < 0.05).

following aerosol or intraperitoneal administration. Serum
GCB levels in the mice treated with GCB i.p. were 3.5-fold
higher than those treated with aerosol GCB at 10 min and
30 min after administered (Figure 1).
3.2. Aerosol GCB Had No Effect on Wound Healing but
Inhibited Osteosarcoma Lung Metastases. In order to mimic
the clinical course of osteosarcoma, K7M3 cells were
injected into the tibia. Micrometastases in the lung were
confirmed by sacrificing 2 mice 3 weeks later. When the
tumors measured 1.5 cm, tail and dorsal skin wounding and
amputation of the affected limb were performed. The mice
were divided into 2 groups and treated with either aerosol
PBS or aerosol GCB 24 hours after amputation. Aerosol
therapy continued twice a week for three weeks. Healing of
the tail, dorsal skin, and amputation site was monitored.
Skin wounds were measured 4, 7, and 10 days after the
initiation of aerosol therapy. There was no difference in
wound healing of the tail or dorsal skin between the aerosol
PBS- and aerosol GCB-treated mice (Figures 2(a) and 2(b)).
Similar to dorsal and tail wounds, aerosol GCB also did not
affect the healing of the amputation site as shown by H&E
staining in 3 different regions (Figure 2(c)).
To determine whether aerosol GCB inhibited lung metastasis, five mice from each treatment group were sacrificed
after 3 weeks of aerosol therapy. Aerosol GCB significantly
decreased the number of visible lung metastases compared to
the aerosol PBS group (Figure 2(d)). Lung weights and the
number of micrometastases were also significantly reduced in
the aerosol GCB group (Figures 2(e) and 2(f)).

3. Results
3.1. Serum GCB Levels following Aerosol versus Intraperitoneal
Administration. We first compared the serum levels of GCB

3.3. Effect of Aerosol GCB on Cell Proliferation and the Number
of Fibroblasts in the Wound Areas. Ki67 is a marker of cell
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Figure 2: Continued.

Sarcoma

5

Aerosol PBS

Aerosol GCB

(d)

P < 0.01

Lung weight (g)

30

20

10

0

PBS treated

GCB aerosol

PBS
GCB
(e)

Lung metastasis number

25

P < 0.01

20
15
10
5
0

PBS

Aerosol GCB

PBS
GCB
(f)

Figure 2: Aerosol GCB inhibited lung metastases but had no effect on wound healing in the tail, dorsal skin, or bone. (a) Representative
appearance of the dorsal wound on days 1 and 10 in the mice treated with aerosol PBS (top row) or aerosol GCB (bottom row). (b) The areas
of each wound in the aerosol PBS and aerosol GCB groups were measured 1, 4, 7, and 10 days after treatment (P > 0.05 for each group).
(c) Representative H&E sections from the wounded tail, dorsal skin, and postamputation area 7 days following wounding. (d–f ) Aerosol
GCB inhibited the growth of osteosarcoma lung metastases as assessed visually (d), by the lung weight (e), and by the mean number of lung
metastases (f ) (P < 0.01).
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Figure 3: Effect of aerosol GCB on cell proliferation and fibroblast numbers associated with wound healing. The dorsal and tail skin wounds
from the mice treated with aerosol PBS or aerosol GCB were examined on day 7. (a) Cell proliferation was assessed using Ki67. (b) Fibroblast
numbers were assessed using anti-fibroblast antibody. The positive areas were quantified by SimplePCI groups obtained from five h.p.f areas
and compared using Student’s t-test. P > 0.05 for all graphs.

proliferation. We therefore quantified the number of Ki67+
cells in the tail and dorsal skin wounds 7 days after treatment
with aerosol therapy. There was no difference in the positive
areas for Ki67 staining between aerosol PBS and aerosol GCB
(Figure 3(a), P > 0.05 for both dorsal and tail wounds). In
addition, quantification of the positive areas for fibroblasts
using immunohistochemistry also showed no difference between aerosol PBS and aerosol GCB (Figure 3(b), P > 0.05 for
both dorsal and tail wounds). These results demonstrate that
aerosol GCB had no effect on cell proliferation or the number
of fibroblast cells during wound healing.
3.4. Aerosol GCB Did Not Affect the 3 Critical Phases of Wound
Healing. Wound repair typically consists of three phases:
initial inflammation, followed by proliferation and finally
remodeling. To determine whether aerosol GCB affects
wound-induced inflammation, we quantified the number of

mast cells in the wound tissues using toluidine staining, the
number of macrophages using F4/80 antibody staining, and
the ratio of M1 to M2 macrophages. M1 macrophages, which
inhibit cell proliferation and cause tissue damage, were
identified and quantified using iNOS staining. M2 macrophages, which promote cell proliferation and tissue repair,
were identified and quantified using the anti-mannose receptor antibody. Both types of macrophages are important for
normal wound healing as is the M1/M2 ratio. Aerosol GCB
had no effect on the number of mast cells (Figure 4(a),
P > 0.05) or the number of M1 and M2 macrophages (Figure
4(b), P > 0.05) in both tail and dorsal wounds. In addition, we
showed that the M1/M2 ratio in the tail and dorsal wounds
did not differ between aerosol PBS- and aerosol GCB-treated
mice (M1 Figure 4(c), P > 0.05; M2 Figure 4(d), P > 0.05).
These results demonstrated that aerosol GCB does not affect
the first phase of wound healing, that is, wound-induced
inflammation in the mice.
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Figure 4: Effect of aerosol GCB on mast cell and macrophage infiltration and M1/M2 wound content. The dorsal and tail skin wounds from
the mice treated with aerosol PBS or aerosol GCB were examined on day 7 for (a) mast cells using toluidine blue and (b) macrophage content
using F4/80 antibody. (c) M1 macrophages were identified by anti-iNOS; (d) M2 macrophages were identified using anti-mannose receptor.
The positive areas were quantified by SimplePCI groups obtained from five h.p.f areas and compared using Student’s t-test. P > 0.05 for all
graphs.

We next determined whether aerosol GCB affected
endothelial cell proliferation and angiogenesis, both critical
functions in the second phase of wound healing.
Endothelial cells play an important role in angiogenesis
in wound-healing process.
To explore whether GCB affects endothelial cell growth
and recruitment in wound healing, we quantified the
number of CD31+ cells (a marker expressed by endothelial
cells) in dorsal and tail wound tissues 7 days after aerosol
PBS or aerosol GCB. There was no difference in CD31
staining in the tail and dorsal skin wounds between aerosol
PBS- and aerosol GCB-treated mice (Figure 5(a), P > 0.05).
VEGFR-2 has been shown to mediate almost all of the
known cellular responses to VEGF [29]. We therefore
measured the density of VEGFR-2+ cells in the wound areas
and once again found no difference between the aerosol PBSand aerosol GCB-treated groups (Figure 5(b), P > 0.05). These
results indicate that aerosol GCB did not inhibit angiogenesis
(an important process in wound dealing) or interfere with the
growth of endothelial cells.
To determine whether aerosol GCB affected tissue
remodeling (the third phase of wound healing), we quantified IL-10 and FGF-2 (bFGF), both of which are critical
cytokines for the remodeling phase of wound healing.
IL-10 plays an important role in wound healing through
its function to inhibit the infiltration of neutrophils and
macrophages toward the site of the wound area during this
phase [28]. We measured the positive areas of IL-10 in
dorsal wound and tail wound sections 7 days after GCB
treatment. Again, we showed no difference in tail or dorsal

wounds (Figure 6(a), P > 0.05) between aerosol GCB- and
aerosol PBS-treated mice. FGF-2 or bFGF mediates the
formation of new blood vessels that are critical in the
wound-healing process following surgery. Different studies
demonstrated a correlation between reduced FGF-2 expression and wound-healing disorders [16, 30, 31, 33].
mRNA levels of FGF-2 were reduced during wound healing
in healing-impaired genetically diabetic mice compared
with control mice [38]. Expression of FGF-2 was found to
be upregulated after injury in normal but not in diabetic
rats. Impaired would healing was seen in aged mice, and
this impairment was associated with reduced levels of
FGF-2 [33]. Finally, when FGF-2 null mice were used for
wound-healing studies, they showed delayed healing, while
there was no delay seen in FGF-1-knockout mice [30, 31]
Similar to our findings with IL-10, there was no difference
in the expression of FGF-2 (bFGF) in the dorsal and tail
wounds between the mice treated with aerosol PBS and
aerosol GCB (Figure 6(b), P > 0.05).
3.5. Effect of Aerosol GCB on Wound Healing following
Amputation. Healing of the bone and tissue following
amputation and tumor removal is a critical part of the
patient recovery process. We therefore monitored healing of
the amputated area every other day. The amputation woundhealing process in the mice following aerosol GCB administration was not delayed compared with the mice
treated with aerosol PBS. Similar to what we observed in the
tail and dorsal skin wounds, there was no difference in
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Figure 5: Effect of aerosol GCB on CD31 and VEGFR in the wound area. The dorsal and tail skin wounds from the mice treated with aerosol
PBS or aerosol GCB were examined on day 7 using (a) anti-CD31 or (b) anti-VEGFR The positive areas were quantified by SimplePCI
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fibroblast proliferation, CD31 expression, VEGFR-2 expression,
or the wound-associated cytokines FGF-2 (bFGF) and IL-10
between aerosol PBS and GCB groups (Figure 7).

4. Discussion
Combination chemotherapy given both pre- and postoperatively has raised the overall survival of patients with
primary nonmetastatic osteosarcoma from 20 to 65% [1–3].
However, despite the use of aggressive multiagent chemotherapy, 30–35% of patients who have no detectable metastasis at the time of diagnosis develop pulmonary metastases
following surgical resection and adjuvant chemotherapy. This
statistic has not improved in >30 years, and patients who
develop lung metastases have a significantly reduced longterm survival [4, 5]. Equally disturbing is that there has been
relatively little success in treating relapsed patients with
surgical resection of metastases in the lung, which is the most
effective approach [32]. A recent analysis showed that the

median time to progression in multiple Phase II trials in the
Children’s Oncology Group for children and adolescents with
relapsed osteosarcoma was ∼4 months [34]. Furthermore, no
responses were seen in multiple Phase I trials from a single
institution [35]. Due to the absence of effective secondary
agents and the poor response rates to date for relapsed patients, it is critical to identify conditions that put the patients
at a higher risk for relapse.
Postoperative chemotherapy is usually not initiated for
2–8 weeks after tumor resection, depending upon the postoperative course, as chemotherapy can interfere with the
wound-healing process and the production of cytokines at the
wound site that have been shown to be critical to the healing
process. This leaves the patient in a potential vulnerable
setting as the tumor cells are free to divide and grow unchecked. Delays > 2 weeks postoperatively correlate with
a poorer overall survival [7, 8]. Two independent retrospective
studies showed that increased time from the definitive surgery
to the resumption of chemotherapy was associated with an
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increased risk of death in patients who presented with localized osteosarcoma [7, 8]. A study from the Children’s
Oncology Group (COG) showed that, of 703 patients analyzed, resumption of chemotherapy ranged from 3 to 97 days
following resection, with >50% of patients going >2 weeks
without treatment and 22% having chemotherapy delays in
excess of 21 days [8]. The times to chemotherapy resumption
following surgery were dependent on several factors including
the type of surgery and surgical margins. Location of the
tumor (proximal versus distal extremity), tumor size (< or
≥9 cm), and % necrosis did not play a role. There was a significant decrease in overall survival in those patients that had
a delay of >16 days. Patients with a delay in excess of 21 days
had a 57% increased risk of death. These findings were
confirmed in a more recent analysis of 77 patients with
a median follow-up time of 11 years [7]. Prolonged time to the
resumption of chemotherapy was once again associated with
an inferior overall survival, and 75% of patients had delays
beyond 21 days. Additionally concerning is that a recent study
showed that the median time interval between the last
neoadjuvant chemotherapy before surgery and the first dose

of chemotherapy postoperatively was 50–63 days. This prolonged interval with no treatment gives the micrometastases
in the lung that were not eradicated by the neoadjuvant
therapy the opportunity to grow. Once a patient relapses with
lung metastases, effective therapeutic options are limited as
salvage chemotherapy has made no impact on long-term
survival [36]. Therefore, the time a patient spends in the
postoperative period without receiving chemotherapy puts
the patient at significant risk. Finally, patients with a poor
tumor response were found to have a significantly increased
risk for relapse if there was a delay of >24 days postoperatively
in the initiation of chemotherapy compared to those with
a good tumor response [9]. This is the most vulnerable
population as histologic response correlates with both
disease-free and overall survival [9]. As chemotherapy delays
increased, both populations were at higher risk for relapse and
decreased survival [9]. Therefore, identifying treatments that
can kill residual tumor cells in the lung which can be initiated
in the immediate postoperative period because they have no
adverse effect on the wound-healing process has the potential
to decrease the relapse rate in both good and poor responders.
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Figure 7: Aerosol GCB did not affect bone healing following
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the mice 14 days after amputation for fibroblasts, CD31, VEGFR-2,
FGF-2 (bFGF), and IL-10.

Such a strategy can have a significant impact on the long-term
survival of patients.
Our current investigations show that aerosol GCB results
in significantly lower serum levels compared with its systemic
administration. The dose used in our studies was 1/10th the
systemic dose normally given to evaluate efficacy [22]. We
have previously evaluated the efficacy of aerosol versus i.p.
GCB against both primary OS and OS lung metastases [22].
Treatment in these studies was similar to that in the present
investigations. When the primary tumor reached 130 mm3
and micrometastases were present in the lung, the mice
were treated 3 times weekly for 3 weeks. While aerosol GCB

was effective against both the primary tumor and the lung
metastases, i.p. GCB at the equivalent dose was only effective
against the primary tumor. GCB given i.p. was not effective
against the OS lung metastases [22]. Since i.p. GCB was not
effective against lung metastases, we did not evaluate the effect
of systemic GCB on wound healing. Our present studies
focused on evaluating the simultaneous efficacy of aerosol
GCB against pulmonary metastases and its effect on wound
healing. The therapeutically appropriate dose of i.p. GCB
would yield even higher serum GCB levels which are more
likely to interfere with the healing process. The goal of our
study was to evaluate the simultaneous activity of aerosol
delivery of the drug on established lung metastases in the
setting of a surgical resection. Supportive of the safety and
tolerability of aerosol GCB are investigations showing that
there was no organ or hematologic toxicity following 5 weeks
of aerosol GCB given 3 times per week [21, 22]. More importantly, our present investigations show that aerosol GCB
initiated 48 hours following amputation of the limb with the
primary osteosarcoma tumor inhibited the growth and
eradicated established micrometastases in the lung without
interfering with wound healing in the skin or bone. Aerosol
GCB had no effect on the 3 phases of wound healing in the
dorsal skin, tail, or bone. Cell proliferation, the number of
fibroblasts and mast cells, macrophage recruitment, and the
ratio of Type I to Type II macrophages in the dorsal skin and
tail wounds of the mice treated with aerosol GCB were similar
to those of the mice treated with aerosol PBS.
Anti-VEGF therapy has been shown to result in late
wound dehiscence [37]. Aerosol GCB did not inhibit endothelial cell growth or VEGF levels in the wounds and had
no effect on the production of either IL-10 or FGF-2 (bFGF).
Similarly, when the wound at the amputation site was examined, treatment with aerosol GCB had no effect on CD31,
VEGF, bFGF, IL-10, or the number of fibroblasts. This is the
first demonstration that aerosol GCB can have a therapeutic
effect on lung metastases without interfering with wound
healing following surgical resection of the primary tumor,
a critical process in the treatment regimen for osteosarcoma.
Taken together, our data suggest that the initiation of aerosol
GCB in the immediate postoperative period has the potential
to eradicate lung micrometastases without fear of interfering
with the postoperative healing process in the skin or the
bone which can delay the resumption of the systemic
chemotherapy. Eradication of lung metastases during this
period when systemic chemotherapy has been suspended
may prevent relapse and result in an increase in the eventfree and overall survival. Patients who develop lung metastases have a 5-year survival rate of only 20% [4, 5].

5. Conclusion
Salvage chemotherapy has made little impact on this survival rate. Aggressive surgical removal of the metastases in
combination with salvage chemotherapy only rescues about
40% of patients [6]. As the safety of aerosol GCB has already
been demonstrated in adult patients [24], our data support the
concept of using aerosol GCB as a bridge after tumor resection and the initiation of clinical trials using aerosol GCB

Sarcoma
in children and adolescents with osteosarcoma in the immediate postoperative period.
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